LYCIA THERAPEUTICS

Founded in 2019, we are privately held and backed by a syndicate of blue-chip investors. We are headquartered and have laboratory space in the thriving South San Francisco biotech hub... We are led by a team of seasoned industry executives who bring a mix of emerging biotech and large pharma experience and expertise. Our Board of Directors and Scientific Advisory Board comprise renowned industry leaders and academic visionaries whose strategic guidance and insights are helping support the growth of our company and advancement of our pipeline... Our pioneering LYTAC (Lysosomal Targeting Chimera) Platform enables targeted degradation of extracellular proteins. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients.

Also known as: Lycia Therapeutics, Inc.

Primary location: South San Francisco United States